annual meeting program - American Society of Clinical Oncology

Saturday, June 5, 2010
Brd. 16D Race and overall survival in acute myeloid leukemia. (Abstract #6570)
J. M. Bierenbaum, Y. Ning, M. Tidwell, I. Gojo, M. R. Baer
Brd. 16E Prognostic factors associated with progression of myelodysplastic
syndromes (MDS) to acute myeloid leukemia (AML) in patients (pts) treated
with decitabine. (Abstract #6571)
A. Fullmer, G. Borthakur, T. M. Kadia, G. Garcia-Manero, E. Jabbour
Brd. 16F CPX-351 IN AML after failed induction with cytarabine and daunorubicin.
(Abstract #6572)
J. E. Lancet, E. J. Feldman, J. E. Cortes, D. Hogge, M. S. Tallman, T. Kovacsovics,
A. C. Louie
Brd. 16G Incidence of unconventional infections (UC) in patients with acute
myelogenous leukemia (AML) treated with clofarabine (CLO)-containing
induction therapy. (Abstract #6573)
R. Knoebel, A. R. McQuary, E. Estey, P. S. Becker
Brd. 16H Activity of azacitidine in chronic myelomonocytic leukemia. (Abstract #6574)
R. B. Costa
Brd. 17A BCR-ABL monitoring in imatinib-treated patients with chronic myelogenous
leukemia. (Abstract #6575)
A. H. Teitelbaum, H. J. Henk, V. Bollu
Brd. 17B Expression of CD74 by AML blasts and cell lines, and enhanced in vitro
cytotoxicity of anti-CD74 antibody after interferon-gamma (IFN-�) treatment.
(Abstract #6576)
J. D. Burton, R. Stein, A. Chandra, S. Chen, N. Mishra, T. Shah, D. M. Goldenberg
Brd. 17C Central nervous system disease and acute myeloid leukemia or chronic
myeloid leukemia: Cytogenetic profile. (Abstract #6577)
F. Shihadeh, V. K. Reed, A. Mazloom, J. Phan, H. Kantarjian, S. Faderl,
B. S. Dabaja
Brd. 17D A phase III randomized, double-blind, placebo controlled trial of North
American (NA) ginseng (Panax quinquefolium) extract (CVT-E002) in patients
with chronic lymphocytic leukemia: Effect on respiratory infection and
antibiotic use. (Abstract #6578)
K. P. High, L. D. Case, R. D. Siegel, J. Metzner-Sidurski, J. C. Krauss,
B. Chinnasami, G. H. Sanders, S. Rousey, G. J. Lesser, E. G. Shaw
Brd. 17E Epidemiology, risk factors, and outcomes of invasive fungal infection in
adults with acute myelogenous leukemia undergoing intensive induction
chemotherapy. (Abstract #6579)
K. Lu, D. Neofytos, A. Blackford, A. H. Seung, J. E. Karp
Brd. 17F Family history (FH) of women with breast cancer (BC) and acute
myelogenous leukemia (AML). (Abstract #6580)
K. A. Reiss, R. R. Yehia, D. Rangachari, A. Blackford, H. Carraway, V. Stearns,
R. J. Arceci, J. E. Karp
Brd. 17G Serum interleukin-6, cardiovascular disease, and mortality in chronic
lymphocytic leukemia. (Abstract #6581)
D. E. Dawe, J. Yoon, S. Gibson, J. B. Johnston
Brd. 17H Treatment-related AML and AML evolving from MDS: Similar outcomes
following treatment with amonafide plus cytarabine. (Abstract #6582)
M. A. Sekeres, S. L. Allen, S. R. Mohan, A. S. Lundberg, H. P. Erba
Brd. 18A Lenalidomide and rituximab for the initial treatment of chronic lymphocytic
leukemia: Report of an ongoing study. (Abstract #6583)
D. F. James, J. R. Brown, L. Werner, W. G. Wierda, K. R. Rai, J. Gould,
J. E. Castro, L. Rassenti, D. S. Neuberg, T. J. Kipps
Brd. 18B Four routinely recorded parameters define four distinct prognostic groups in
AML. (Abstract #6584)
J. R. Novotny, H. Nueckel, A. Aisenbrey, U. Duehrsen
95
SATURDAY